

## ELDER PHARMACEUTICALS LIMITED

## STANDALONE UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER ENDED 31ST DECEMBER, 2014

(RS IN LACS)

|        |   | STANDALONE        |                         |   |                   |                  |                                |
|--------|---|-------------------|-------------------------|---|-------------------|------------------|--------------------------------|
| SR.NO. | PARTICULARS   | 3 months ended    | Previous 3 months ended | Corresponding 3 months ended in previous year | SIX MONTHS ENDED  |                  | Previous accounting year ended |
|        |   | 31/12/2014        | 30/09/2014              | 31/12/2013                                    | 31/12/2014        | 31/12/2013       | 30/06/2014                     |
|        |   | Unaudited         | Unaudited               | Unaudited                                     | Unaudited         | Unaudited        | Audited-12 months              |
|        | <b>INCOME FROM OPERATIONS</b>   |                   |                         |   |                   |                  |                                |
| a      | NET SALES / INCOME FROM OPERATIONS (Net of excise duty)   | 3503.19           | 8380.77                 | 13672.05                                      | 11883.96          | 28969.31         | 48070.12                       |
| b      | OTHER OPERATING INCOME  | 52.30             | 34.80                   | 81.11   | 87.10             | 130.53           | 277.30                         |
|        | <b>TOTAL INCOME FROM OPERATIONS(NET)(A+B)</b>   | <b>3555.50</b>    | <b>8415.57</b>          | <b>13753.16</b>                               | <b>11971.07</b>   | <b>29099.84</b>  | <b>48347.42</b>                |
| 2      | <b>EXPENSES</b>   |                   |                         |   |                   |                  |                                |
|        | a) Cost of materials consumed   | 1078.44           | 953.23                  | 1526.05                                       | 2031.67           | 2645.96          | 4884.40                        |
|        | b) Purchases of stock-in-trade  | 1715.49           | 6356.36                 | 3583.30                                       | 8071.85           | 6476.13          | 13182.44                       |
|        | c) Changes in inventories of finished goods, work-in-progress and stock-in-trade                            | 997.67            | -637.31                 | 624.56  | 360.36            | 2542.34          | 12768.37                       |
|        | d) Employee benefits expense.   | 1513.50           | 1634.55                 | 2602.91                                       | 3148.05           | 5192.63          | 11638.74                       |
|        | e) Depreciation and amortisation expense  | 657.64            | 924.70                  | 743.77  | 1582.34           | 1486.06          | 2915.77                        |
|        | f) Other expenses   | 1418.11           | 2663.13                 | 2749.20                                       | 4081.24           | 5514.86          | 14683.58                       |
|        | <b>TOTAL EXPENSES</b>   | <b>7380.85</b>    | <b>11894.66</b>         | <b>11829.79</b>                               | <b>19275.51</b>   | <b>23857.98</b>  | <b>60073.30</b>                |
| 3      | <b>PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, FINANCE COSTS AND EXCEPTIONAL ITEMS (1-2)</b>         | <b>(3,825.36)</b> | <b>(3,479.09)</b>       | <b>1923.37</b>                                | <b>(7304.45)</b>  | <b>5241.86</b>   | <b>(11,725.88)</b>             |
| 4      | OTHER INCOME  | 70.56             | 817.35                  | 218.42  | 887.91            | 744.95           | 1513.24                        |
| 5      | <b>PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS AND EXCEPTIONAL ITEMS (3-4)</b>              | <b>(3,754.80)</b> | <b>(2,661.74)</b>       | <b>2141.79</b>                                | <b>(6416.54)</b>  | <b>5986.81</b>   | <b>(10,212.64)</b>             |
| 6      | Finance costs   | 3543.87           | 2030.92                 | 4280.17                                       | 5574.79           | 7643.63          | 26006.43                       |
| 7      | <b>PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)</b>        | <b>(7,298.67)</b> | <b>(4,692.66)</b>       | <b>(2138.38)</b>                              | <b>(11991.33)</b> | <b>(1656.82)</b> | <b>(36,219.07)</b>             |
| 8      | EXCEPTIONAL ITEMS   | ---               | ---                     | ---   | ---               | ---              | 38004.43                       |
| 9      | <b>PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)</b>  | <b>(7,298.67)</b> | <b>(4692.66)</b>        | <b>(2138.38)</b>                              | <b>(11991.33)</b> | <b>(1656.82)</b> | <b>1785.36</b>                 |
| 10     | TAX EXPENSES  | ---               | ---                     | ---   | ---               | ---              | 67.13                          |
| 11     | <b>NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9-10)</b>  | <b>(7,298.67)</b> | <b>(4692.66)</b>        | <b>(2138.38)</b>                              | <b>(11991.33)</b> | <b>(1656.82)</b> | <b>1718.23</b>                 |
| 12     | EXTRAORDINARY ITEM (NET OF TAX EXP. RS.--Lac)   | ---               | ---                     | ---   | ---               | ---              | ---                            |
| 13     | <b>NET PROFIT/(LOSS) FOR THE PERIOD (11-12)</b>   | <b>(7,298.67)</b> | <b>(4692.66)</b>        | <b>(2138.38)</b>                              | <b>(11991.33)</b> | <b>(1656.82)</b> | <b>1718.23</b>                 |
| 14     | SHARE OF PROFIT/(LOSS) OF ASSOCIATES  | ---               | ---                     | ---   | ---               | ---              | ---                            |
| 15     | MINORITY INTEREST   | ---               | ---                     | ---   | ---               | ---              | ---                            |
| 16     | <b>NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTEREST AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)</b> | <b>(7,298.67)</b> | <b>(4692.66)</b>        | <b>(2138.38)</b>                              | <b>(11991.33)</b> | <b>(1656.82)</b> | <b>1718.23</b>                 |
| 17     | PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF SHARES Rs. 10/-)  | 2053.69           | 2053.69                 | 2053.69                                       | 2053.69           | 2053.69          | 2053.69                        |
| 18     | RESERVE EXCLUDING REVALUATION RESERVES AS PER BALANCE SHEET OF PREVIOUS ACCOUNTING YEAR                     | ---               | ---                     | ---   | ---               | ---              | 76502.65                       |
| 19i    | <b>EARNINGS PER SHARE (before extraordinary items) (of Rs.10/-each) (not annualised)</b>                    |                   |                         |   |                   |                  |                                |








ELDER PHARMACEUTICALS LIMITED  
STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Rs. In Lacs)

| PARTICULARS                                | AS AT 31.12.14    | AS AT 30.06.14    |
|--|-------------------|-------------------|
|  | Unaudited         | Audited           |
| <b>A EQUITY AND LIABILITIES</b>            |                   |                   |
| <b>1 Shareholder's Funds</b>               |                   |                   |
| (a) Share Capital                          | 2,053.69          | 2,053.69          |
| (b) Reserve and Surplus                    | 64,511.34         | 76,502.62         |
| (C) Pending call Money                     | 2.97              | 2.97              |
| <b>Sub-Total Shareholders' funds</b>       | <b>66,568.00</b>  | <b>78,559.28</b>  |
| <b>2 Non-current liabilities</b>           |                   |                   |
| (a) Long term borrowings                   | 38,517.88         | 40,058.86         |
| (b) long -term provisions                  | 1,459.47          | 1,459.57          |
| <b>Sub-total _non_Current- liabilities</b> | <b>39,977.35</b>  | <b>41,518.43</b>  |
| <b>3 Current Liabilities</b>               |                   |                   |
| (a) Short- term borrowings                 | 20,177.70         | 19,553.58         |
| (b) Trade payable                          | 3,467.16          | 3,382.52          |
| (c) Other current liabilities              | 24,877.96         | 28,709.13         |
| (d) Short -term provisions                 | 336.01            | 21,854.22         |
| <b>Sub-total _Current- liabilities</b>     | <b>48,858.83</b>  | <b>73,499.45</b>  |
| <b>TOTAL-EQUITY AND LIABILITIES</b>        | <b>155,404.18</b> | <b>193,577.16</b> |
| <b>B ASSETS</b>                            |                   |                   |
| <b>1 Non-current assets</b>                |                   |                   |
| (a) Fixed assets                           | 72,546.07         | 73,916.89         |
| (b) Non -current investments               | 246.27            | 246.27            |
| (c) Deferred tax assets (net)              | 2.85              | 2.85              |
| (d) Long-term loans and advances           | 46,051.05         | 47,280.74         |
| <b>Sub-total -Non-current- assets</b>      | <b>118,846.24</b> | <b>121,446.75</b> |
| <b>2 Current assets</b>                    |                   |                   |
| (a) Current investments                    | 127.00            | 127.00            |
| (b) Inventories                            | 1,872.23          | 2,789.73          |
| (c) Trade receivables                      | 9,410.49          | 8,446.73          |
| (d) cash and cash equivalents              | 15,999.16         | 53,838.60         |
| (e) Short-term loans and advances          | 1,824.62          | 3,076.54          |
| (f) Other current assets                   | 7,324.44          | 3,851.81          |
| <b>Sub-total -current- assets</b>          | <b>36,557.94</b>  | <b>72,130.41</b>  |
| <b>TOTAL ASSETS</b>                        | <b>155,404.18</b> | <b>193,577.16</b> |

For Elder Pharmaceuticals Ltd

  
Alok Jagdish Saxena  
Managing Director & CEO

Place: Mumbai  
Date : 13th February, 2015



## ELDER PHARMACEUTICALS LIMITED

## CONSOLIDATED UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER ENDED 31ST DECEMBER, 2014

(RS IN LACS)

| SR.NO. | PARTICULARS  | 3 months ended    | Previous 3 months ended | Corresponding 3 months ended in previous year | SIX MONTHS ENDED  |                  | Previous accounting year ended |
|--------|--|-------------------|-------------------------|---|-------------------|------------------|--------------------------------|
|        |  | 31/12/2014        | 30/09/2014              | 31/12/2013                                    | 31/12/2014        | 31/12/2013       | 30/06/2014                     |
|        |  | Unaudited         | Unaudited               | Unaudited                                     | Unaudited         | Unaudited        | Audited-12 months              |
|        | <b>INCOME FROM OPERATIONS</b>  |                   |                         |   |                   |                  |                                |
| a      | NET SALES / INCOME FROM OPERATIONS (Net of excise duty)  | 15689.52          | 20030.57                | 38421.64                                      | 35720.09          | 65589.77         | 100613.49                      |
| b      | OTHER OPERATING INCOME   | 103.12            | 283.27                  | 285.02  | 386.39            | 393.02           | 277.30                         |
|        | <b>TOTAL INCOME FROM OPERATIONS(NET)(A+B)</b>  | <b>15792.64</b>   | <b>20313.84</b>         | <b>38706.66</b>                               | <b>36106.48</b>   | <b>65982.79</b>  | <b>100890.79</b>               |
| 2      | <b>EXPENSES</b>  |                   |                         |   |                   |                  |                                |
|        | a)Cost of materials consumed   | 1256.99           | 1062.72                 | 1905.74                                       | 2319.71           | 3174.95          | 5281.40                        |
|        | b)Purchases of stock-in-trade  | 8453.99           | 12585.47                | 18637.95                                      | 21039.46          | 28689.33         | 47183.06                       |
|        | c)Changes in inventories of finished goods, work-in-progress and stock-in-trade                            | 1068.62           | -301.90                 | 536.18  | 766.72            | 2659.25          | 11826.98                       |
|        | d) Employee benefits expense.  | 4305.97           | 4490.88                 | 7413.37                                       | 8796.85           | 12290.16         | 22190.04                       |
|        | e)Depreciation and amortisation expense  | 892.77            | 1132.15                 | 1106.85                                       | 2024.92           | 2029.10          | 3612.55                        |
|        | f)Other expenses   | 3759.57           | 5034.19                 | 6862.15                                       | 8793.76           | 11417.64         | 22328.24                       |
|        | <b>TOTAL EXPENSES</b>  | <b>19737.91</b>   | <b>24003.51</b>         | <b>36462.24</b>                               | <b>43741.42</b>   | <b>60260.43</b>  | <b>112422.27</b>               |
| 3      | <b>PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME,FINANCE COSTS AND EXCEPTIONAL ITEMS (1-2)</b>         | <b>(3,945.27)</b> | <b>(3,689.67)</b>       | <b>2244.42</b>                                | <b>(7634.94)</b>  | <b>5722.36</b>   | <b>(11,531.48)</b>             |
| 4      | OTHER INCOME   | 93.84             | 932.25                  | 437.23  | 1026.09           | 1080.90          | 2565.82                        |
| 5      | <b>PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE FINANCE COSTS AND EXCEPTIONAL ITEMS (3-4)</b>             | <b>(3,851.43)</b> | <b>(2,757.42)</b>       | <b>2681.65</b>                                | <b>(6608.85)</b>  | <b>6803.26</b>   | <b>(8,965.66)</b>              |
| 6      | Finance costs  | 4504.92           | 2318.27                 | 4934.71                                       | 6823.19           | 8615.92          | 27563.12                       |
| 7      | <b>PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXCEPTIONAL ITEMS (5-6)</b>       | <b>(8,356.35)</b> | <b>(5,075.69)</b>       | <b>(2253.06)</b>                              | <b>(13432.04)</b> | <b>(1812.66)</b> | <b>(36,528.78)</b>             |
| 8      | EXCEPTIONAL ITEMS  | ---               | 403.30                  | 48.01   | 483.89            | 48.01            | 37127.33                       |
| 9      | <b>PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7-8)</b>   | <b>(8,356.35)</b> | <b>(4672.39)</b>        | <b>(2301.07)</b>                              | <b>(12948.15)</b> | <b>(1860.67)</b> | <b>598.55</b>                  |
| 10     | TAX EXPENSES   | ---               | 14.92                   | 32.45   | 64.92             | 158.42           | 325.68                         |
| 11     | <b>NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (9-10)</b>   | <b>(8,356.35)</b> | <b>(4687.31)</b>        | <b>(2333.52)</b>                              | <b>(13013.07)</b> | <b>(2019.09)</b> | <b>272.87</b>                  |
| 12     | EXTRAORDINARY ITEM (NET OF TAX EXP. RS.--Lac)  | ---               | ---                     | ---   | ---               | ---              | ---                            |
| 13     | <b>NET PROFIT/(LOSS) FOR THE PERIOD (11-12)</b>  | <b>(8,356.35)</b> | <b>(4687.31)</b>        | <b>(2333.52)</b>                              | <b>(13013.07)</b> | <b>(2019.09)</b> | <b>272.87</b>                  |
| 14     | SHARE OF PROFIT/(LOSS) OF ASSOCIATES   | ---               | ---                     | ---   | ---               | ---              | ---                            |
| 15     | MINORITY INTEREST  | ---               | ---                     | ---   | ---               | ---              | ---                            |
| 16     | <b>NET PROFIT/(LOSS) AFTER TAXES, MINORITY INTERES AND SHARE OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)</b> | <b>(8,356.35)</b> | <b>(4687.31)</b>        | <b>(2333.52)</b>                              | <b>(13013.07)</b> | <b>(2019.09)</b> | <b>272.87</b>                  |
| 17     | PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF SHARES Rs. 10/-)   | 2053.69           | 2053.69                 | 2053.69                                       | 2053.69           | 2053.69          | 2053.69                        |
| 18     | RESERVE EXCLUDING REVALUATION RESERVES AS PER BALANCE SHEET OF PREVIOUS ACCOUNTING YEAR                    | ---               | ---                     | ---   | ---               | ---              | 74869.71                       |
| 19i    | <b>EARNINGS PER SHARE (before extraordinary items) (of Rs.10/-each) (not annualised)</b>                   |                   |                         |   |                   |                  |                                |
|        | a) Basic   | <b>(40.69)</b>    | <b>(22.82)</b>          | <b>(11.36)</b>                                | <b>(63.36)</b>    | <b>(9.83)</b>    | <b>1.33</b>                    |







ELDER PHARMACEUTICALS LIMITED  
 CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

| PARTICULARS |  | (Rs. In Lacs)     |                   |
|-------------|--|-------------------|-------------------|
|             |  | AS AT 31.12.14    | AS AT 30.06.14    |
|             |  | Unaudited         | Audited           |
| <b>A</b>    | <b>EQUITY AND LIABILITIES</b>              |                   |                   |
| 1           | <b>Shareholder's Funds</b>                 |                   |                   |
|             | (a) Share Capital                          | 2,053.69          | 2,053.69          |
|             | (b) Reserve and Surplus                    | 68,181.78         | 75,278.22         |
|             | (C) Pending call Money                     | 2.97              | 2.97              |
|             | <b>Sub-Total Shareholders' funds</b>       | <b>70,238.44</b>  | <b>77,334.88</b>  |
| 2           | <b>Non-current liabilities</b>             |                   |                   |
|             | (a) Long term borrowings                   | 40,543.40         | 54,038.37         |
|             | (b) long -term provisions                  | 1,607.47          | 2,120.87          |
|             | (c) Deferred tax liabilities               | 459.82            | 497.22            |
|             | <b>Sub-total _non_Current- liabilities</b> | <b>42,610.69</b>  | <b>56,656.46</b>  |
| 3           | <b>Current Liabilities</b>                 |                   |                   |
|             | (a) Short- term borrowings                 | 34,020.45         | 26,466.43         |
|             | (b) Trade payable                          | 10,165.58         | 9,612.23          |
|             | (c) Other current liabilities              | 29,006.96         | 36,895.39         |
|             | (d) Short -term provisions                 | 336.01            | 21,854.22         |
|             | <b>Sub-total _Current- liabilities</b>     | <b>73,529.00</b>  | <b>94,828.27</b>  |
|             | <b>TOTAL-EQUITY AND LIABILITIES</b>        | <b>186,378.13</b> | <b>228,819.61</b> |
| <b>B</b>    | <b>ASSETS</b>                              |                   |                   |
| 1           | <b>Non-current assets</b>                  |                   |                   |
|             | (a) Fixed assets                           | 96,864.10         | 101,237.53        |
|             | (b) Non -current investments               | 2,559.02          | 183.86            |
|             | (d) Long-term loans and advances           | 29,354.21         | 34,998.25         |
|             | <b>Sub-total -Non-current- assets</b>      | <b>128,777.33</b> | <b>136,419.64</b> |
| 2           | <b>Current assets</b>                      |                   |                   |
|             | (a) Current investments                    | 127.00            | 127.00            |
|             | (b) Inventories                            | 12,139.13         | 12,798.61         |
|             | (c) Trade receivables                      | 18,041.64         | 16,567.65         |
|             | (d) cash and cash equivalents              | 17,171.27         | 54,661.01         |
|             | (e) Short-term loans and advances          | 1,824.62          | 4,195.07          |
|             | (f) Other current assets                   | 8,297.14          | 4,050.63          |
|             | <b>Sub-total -current- assets</b>          | <b>57,600.80</b>  | <b>92,399.97</b>  |
|             | <b>TOTAL ASSETS</b>                        | <b>186,378.13</b> | <b>228,819.61</b> |

For Elder Pharmaceuticals Ltd

Alok Jagdish Saxena  
 Managing Director & CEO

Place: Mumbai  
 Date : 13th February, 2015





To  
The Board of Directors,  
Elder Pharmaceuticals Ltd,  
Elder House, Plot No: C-9,  
Dalia Industrial Estate,  
Off. Veera Desai Road, Andheri (W),  
Mumbai - 400 053.

We have reviewed the accompanying statement of Unaudited Consolidated financial results ('the Statement') of M/s Elder Pharmaceuticals Limited ('the Company') for the quarter ended 31<sup>st</sup> December, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors at its meeting held on February 13, 2015. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, *subject to the effect of such adjustments, if any, as might have been required had the outcome of items listed in paragraphs (a) to (f) below been known*, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results, prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", notified pursuant of the Companies (Accounting Standards) Rules, 2006, (as amended), and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

(a) *The Company's operations and operating results have been materially affected due to various factors. Management believes that the Going Concern Assumption is appropriate and no adjustments have been made in the financial statements for the quarter ended December 31, 2014. However, the appropriateness of the Going Concern Assumption is dependent on the company's ability to streamline its operations as well as infusing requisite finance to meet its short term and long term financial obligations and other statutory liabilities.*

(b) *The Company has accepted Fixed Deposits under Companies (Acceptance of Deposits) Rules, 1975. The Company has defaulted in making payments of fixed deposits of Rs.3,871 lacs and interest thereon of Rs. 726 lacs payable upto December 31, 2014.*







*The Company has preferred an application under section 58A/74(2) of the Companies Act, 1956/2013 against orders dated December 24, 2014 and January 21, 2015 passed by the Company Law Board, Mumbai bench (CLB) directing the Company to refund the outstanding amount to the fixed deposit holders as per terms and conditions of FDRs within 30 days thereof. The CLB has directed to the Company to make compliance in terms of Notification No. F.No. 10/36/2001-CLB dated February 11, 2015 and the matter is still pending.*

- (c) *The Company has defaulted in repayment to Non-Convertible Debentures holders and aggregate sum of Rs. 6,752.79 lacs and Rs. 3,936.88 lacs are due for payment towards principal & interest thereon respectively as at December 31, 2014.*
- (d) *As informed, various cases have been filed against the Company under various Acts and statutes applicable to the Company, the same are being contested by the Company at various foras. The outcome of such cases and their impact on the affairs of the Company cannot presently be determined/ascertained.*
- (e) *The Company has given corporate guarantee to a bank for borrowing by its subsidiary Elder International FZCO, Dubai aggregating to GBP 11.00 million (equivalent to Rs. 10,832.61 lacs) at December 31, 2014. The Bank has initiated legal action for non-payment of loan by the subsidiary.*
- (f) *The statutory dues under various statutes aggregating to Rs. 2,894.45 lacs are due for depositing with the appropriate authorities as at 31st December, 2014.*

**For S .S. KHANDELWAL & CO.**  
**Chartered Accountants**  
**(Firm Registration No: 105064W)**

**(S. S. KHANDELWAL)**  
**Proprietor**  
**Membership No. 031487**



**Mumbai; 13<sup>th</sup> February, 2015**